Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Non-Current Liabilities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Total Non-Current Liabilities data on record, last reported at $243.1 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 27.41% year-over-year to $243.1 million; the TTM value through Dec 2025 reached $243.1 million, up 27.41%, while the annual FY2025 figure was $243.1 million, 27.41% up from the prior year.
  • Total Non-Current Liabilities reached $243.1 million in Q4 2025 per ARQT's latest filing, up from -$158.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $280.3 million in Q3 2024 and bottomed at -$225.2 million in Q1 2024.
  • Average Total Non-Current Liabilities over 5 years is $89.1 million, with a median of $190.8 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 892.99% in 2022, then crashed 156.52% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $110.4 million in 2021, then surged by 117.01% to $239.7 million in 2022, then rose by 5.07% to $251.8 million in 2023, then dropped by 24.25% to $190.8 million in 2024, then increased by 27.41% to $243.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $243.1 million in Q4 2025, -$158.4 million in Q3 2025, and $213.1 million in Q2 2025.